Fig 3. Budesonide treatment promotes outside/in barrier integrity in vivo.

C57B/6 mice were given vehicle or 350–700 μg/kg budesonide (Bud) oropharyngeally (o.p.) on days -2-2, and 10 μg polyI:C o.p. on days 0–2. On day 3, 0.2 mg 4kDa FITC-dextran was instilled o.p. and 1hr later BALF and blood were collected. A-B) BALF and serum were analyzed for FITC-dextran levels using a fluorescent plate reader. C-D) Total protein and albumin levels in BALF were assessed via Bradford and ELISA respectively. Data are mean ± standard deviation. One way ANOVA followed by unpaired Tukey’s multiple comparisons test. ** p< 0.01; ***p<0.001; **** p<0.0001.